Latest Breaking News On - Analysis results - Page 14 : comparemela.com

F. Hoffmann-La Roche Ltd Roche’s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness Roche’s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness Faricimab given every eight weeks and at personalised dosing intervals of up to 16 weeks demonstrated non-inferior visual acuity gains compared to aflibercept given every eight weeks in both studies More than half of participants in the faricimab personalised dosing arms had extended time between treatments to 16 weeks at year one – the first time this level of durability has been achieved in a phase III diabetic macular edema study

United statesUnited kingdomNathalie meetzLevi garrawayDaniel grotzkyPatrick barthKarsten kleineHead of global product developmentAmerican academy of ophthalmologyAmerican optometric associationAmerican society of retina specialists annual meetingNational eye instituteRoche groupPharmaceuticals industryRoche group media relationsChief medical officer